Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It specializes in development and commercialization of innovative therapies for women's health diseases and other endocrine-related disorders. It focuses on product candidate, relugolix, for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer, as well as in RVT-602, for the treatment of female infertility as part of assisted reproduction. The company was founded on February 2, 2016 and is headquartered in Hamilton, Bermuda.
Market Cap | 985.062 Million | Shares Outstanding | 93.905 Million | Avg 30-day Volume | 983.703 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -3.13 |
Price to Revenue | 7.3502 | Debt to Equity | 0.0 | EBITDA | -204.777 Million |
Price to Book Value | 0.0 | Operating Margin | -107.24560000000001 | Enterprise Value | 927.644 Million |
Current Ratio | 2.136 | EPS Growth | 0.075 | Quick Ratio | 2.032 |
1 Yr BETA | 1.8092 | 52-week High/Low | 27.43 / 7.67 | Profit Margin | -115.1755 |
Operating Cash Flow Growth | -158.8319 | Altman Z-Score | -2.1046 | Free Cash Flow to Firm | -249.559 Million |
Please sign in first
none
48.6 Thousand total shares from 6 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
MAREK DAVID C PRINCIPAL EXECUTIVE OFFICER |
|
447,956 | 2022-04-19 | 3 |
LANG MATTHEW GENERAL COUNSEL & CORP. SECY. |
|
276,037 | 2022-04-19 | 6 |
ARJONA FERREIRA JUAN CAMILO CHIEF MEDICAL OFFICER |
|
260,129 | 2022-04-19 | 12 |
MERENDINO LAUREN CHIEF COMMERCIAL OFFICER |
|
174,953 | 2022-04-19 | 2 |
MEHRA UNEEK PRINCIPAL FINANCIAL OFFICER |
|
214,180 | 2022-04-15 | 3 |
|
21,096 | 2021-11-05 | 1 | |
|
21,096 | 2021-11-05 | 1 | |
|
21,096 | 2021-11-05 | 1 | |
|
21,096 | 2021-11-05 | 3 | |
|
0 | 2021-11-05 | 2 | |
|
50,041,181 | 2021-09-28 | 16 | |
KARBE FRANK PRINCIPAL FIN'L & ACCOUNTING |
|
212,296 | 2021-07-07 | 1 |
|
0 | 2020-09-15 | 0 | |
SEELY LYNN PRINCIPAL EXECUTIVE OFFICER |
|
1,889,992 | 2020-04-03 | 0 |
SABLICH KIM CHIEF COMMERCIAL OFFICER |
|
146,710 | 2020-04-03 | 0 |
|
No longer subject to file | 2019-12-27 | 0 | |
|
0 | 2019-12-27 | 0 | |
|
0 | 2019-08-23 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
No longer subject to file | 2019-07-10 | 0 |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
38,341,357 | 2019-01-01 | 0 | |
|
0 | 2018-08-31 | 0 | |
|
38,341,357 | 2018-04-02 | 0 | |
|
7,420,625 | 2018-03-19 | 0 | |
|
7,420,625 | 2018-03-19 | 0 | |
|
37,231,342 | 2017-09-06 | 0 | |
|
0 | 2017-08-18 | 0 | |
|
37,231,342 | 2017-07-01 | 0 | |
|
7,420,625 | 2017-04-17 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
37,231,342 | 2016-10-26 | 0 |
|
0 | 2016-10-26 | 0 | |
|
0 | 2016-10-26 | 0 | |
|
37,231,342 | 2016-10-26 | 0 | |
ROMEO MARIANNE L. HEAD,GLOBAL TRANS. & RISK MGMT |
|
0 | 2016-10-26 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-04-21 16:27:06 -0400 | 2022-04-19 | S | 4,632 | $10.45 | d | 260,129 | direct | 8.8486 | -0.7463 | 8.8486 | 2 | -2.2388 | 4 | |||
2022-04-21 16:28:08 -0400 | 2022-04-19 | S | 8,002 | $10.45 | d | 276,037 | direct | 8.8486 | -0.7463 | 8.8486 | 2 | -2.2388 | 4 | |||
MAREK DAVID C - Director - Officer PRINCIPAL EXECUTIVE OFFICER |
2022-04-21 16:25:00 -0400 | 2022-04-19 | S | 24,594 | $10.45 | d | 447,956 | direct | 8.8486 | -0.7463 | 8.8486 | 2 | -2.2388 | 4 | ||
2022-04-21 16:25:57 -0400 | 2022-04-19 | S | 7,049 | $10.45 | d | 174,953 | direct | 8.8486 | -0.7463 | 8.8486 | 2 | -2.2388 | 4 | |||
MAREK DAVID C - Director - Officer PRINCIPAL EXECUTIVE OFFICER |
2022-04-19 16:46:56 -0400 | 2022-04-15 | A | 134,567 | a | 472,550 | direct | -5.6436 | -9.2079 | 1.0891 | 4 | -9.2079 | 6 | |||
2022-04-19 16:51:02 -0400 | 2022-04-15 | A | 103,703 | a | 264,761 | direct | -5.6436 | -9.2079 | 1.0891 | 4 | -9.2079 | 6 | ||||
2022-04-19 16:48:43 -0400 | 2022-04-15 | A | 103,703 | a | 182,002 | direct | -5.6436 | -9.2079 | 1.0891 | 4 | -9.2079 | 6 | ||||
2022-04-19 16:49:41 -0400 | 2022-04-15 | A | 111,111 | a | 284,039 | direct | -5.6436 | -9.2079 | 1.0891 | 4 | -9.2079 | 6 | ||||
MAREK DAVID C - Director - Officer PRINCIPAL EXECUTIVE OFFICER |
2022-04-19 16:46:56 -0400 | 2022-04-15 | A | 204,808 | a | 204,808 | direct | |||||||||
2022-04-19 16:52:15 -0400 | 2022-04-15 | A | 111,111 | a | 214,180 | direct | -5.6436 | -9.2079 | 1.0891 | 4 | -9.2079 | 6 | ||||
2022-04-07 16:16:51 -0400 | 2022-04-05 | S | 1,922 | $13.78 | d | 161,058 | direct | -4.3448 | -25.1034 | 0.0 | 1 | -28.3448 | 3 | |||
2022-04-07 16:19:29 -0400 | 2022-04-05 | S | 2,436 | $13.78 | d | 172,928 | direct | -4.3448 | -25.1034 | 0.0 | 1 | -28.3448 | 3 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MYOVANT SCIENCES LTD MYOV | 2022-05-20 22:15:03 UTC | 0.3726 | 0.4474 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 21:45:03 UTC | 0.3726 | 0.4474 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 21:15:03 UTC | 0.3726 | 0.4474 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 20:45:03 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 20:15:05 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 19:45:03 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 19:15:04 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 18:45:03 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 18:15:03 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 17:45:03 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 17:15:03 UTC | 0.3728 | 0.4472 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 16:45:04 UTC | 0.3285 | 0.4915 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 16:15:03 UTC | 0.3285 | 0.4915 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 15:45:03 UTC | 0.3285 | 0.4915 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 15:15:03 UTC | 0.3285 | 0.4915 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 14:45:03 UTC | 0.2123 | 0.6077 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 14:15:04 UTC | 0.2123 | 0.6077 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 13:45:03 UTC | 0.2123 | 0.6077 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 13:15:03 UTC | 0.2123 | 0.6077 | 600000 |
MYOVANT SCIENCES LTD MYOV | 2022-05-20 12:45:03 UTC | 0.2123 | 0.6077 | 600000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Enhanced Index Plus Fund | MYOV | -302.0 shares, $-2280.1 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | MYOV | -2.0 shares, $-15.1 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | MYOV | -297.0 shares, $-2242.35 | 2020-03-31 | N-PORT |